Mycophenolate Mofetil Accord Healthcare (Mycophenolate Mofetil)

The drug blocks inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo guanosine nucleotide synthesis. By limiting guanosine availability, it suppresses the proliferation of T‑ and B‑lymphocytes, reducing immune responses that can damage transplanted organs or inflamed kidneys.

Dosing is individualized. The prescribing clinician determines the appropriate amount based on the patient’s condition, body weight, renal function, and other concurrent therapies. Patients should follow the exact regimen provided by their healthcare professional.

Mycophenolate Mofetil is classified as Pregnancy Category X because it can cause fetal harm. It is contraindicated in pregnancy, and women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, and nursing is generally discouraged.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to achieve synergistic immunosuppression while allowing lower doses of each agent.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not expose the medication to excessive heat or humidity, and keep it out of reach of children.

Mycophenolate Mofetil is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact dosing schedule—once or twice daily—depends on the therapeutic indication and patient-specific factors.

Serious risks include severe infections due to immunosuppression, bone‑marrow suppression leading to leukopenia or anemia, and potential liver injury. Patients should be monitored regularly for signs of infection, blood‑cell abnormalities and hepatic dysfunction.

The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or any component of the formulation, and patients with severe uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment.